https://imedic.health/en/health/news/daraxonrasib-pancreatic-cancer-ras-inhibitor-survival-trial iMedic en 2026-06-02 Daraxonrasib Pancreatic Cancer Trial: RAS Inhibitor Nearly Doubles Survival https://imedic.health/en/health/news/subjective-age-sleep-quality-daytime-functioning iMedic en 2026-06-02 Feeling Older Than Your Age May Signal Sleep and Daytime Health Risks https://imedic.health/en/health/news/glp1-weight-loss-drugs-breast-cancer-risk iMedic en 2026-06-02 GLP-1 Weight-Loss Drugs and Breast Cancer Risk: What the Evidence Suggests https://imedic.health/en/health/news/insomnia-cancer-risk-sleep-health-oncology-research iMedic en 2026-06-02 Insomnia and Cancer Risk: Why Sleep Health Is Entering Oncology Research https://imedic.health/en/health/news/amivantamab-injection-resistant-head-neck-cancer iMedic en 2026-06-03 Amivantamab Injection Shows Promise for Resistant Head and Neck Cancer https://imedic.health/en/health/news/empagliflozin-ketosis-anaplerotic-therapy-sglt2-inhibitor-safety iMedic en 2026-06-03 Empagliflozin Ketosis Research Points to Anaplerotic Strategy for SGLT2 Inhibitor Safety https://imedic.health/en/health/news/pgdhi-glp1-muscle-repair-weight-loss-drug iMedic en 2026-06-03 PGDHi Muscle-Repair Drug May Protect Strength During GLP-1 Weight Loss https://imedic.health/en/health/news/pharmacist-phone-calls-ldl-cholesterol-medication-adherence iMedic en 2026-06-03 Pharmacist Phone Calls May Improve LDL Cholesterol Medication Adherence